Patents by Inventor Emma Masteller

Emma Masteller has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-CSF1R Antibody and Anti-PD-1 Antibody Combination Therapy for Cancer
    Publication number: 20230212299
    Abstract: Methods of treating cancer with antibodies that bind colony stimulating factor 1 receptor (CSF1R) in combination with PD-1/PD-L1 inhibitors are provided.
    Type: Application
    Filed: December 21, 2022
    Publication date: July 6, 2023
    Applicants: Five Prime Therapeutics, Inc., Bristol-Myers Squibb Company
    Inventors: Brian Wong, Julie Hambleton, Robert Sikorski, Emma Masteller, Kevin Hestir, David Bellovin, Katherine E. Lewis
  • Combination Anti-CSF1R and Anti-PD-1 Antibody Combination Therapy for Pancreatic Cancer
    Publication number: 20230192870
    Abstract: The present invention relates to methods of treating pancreatic cancer with particular dosage regimes of antibodies that bind colony stimulating factor 1 receptor (CSF1R) (e.g. cabiralizumab) in combination with antibodies that bind programmed cell death 1 (PD-1) (e.g. nivolumab).
    Type: Application
    Filed: July 14, 2022
    Publication date: June 22, 2023
    Applicants: Five Prime Therapeutics, Inc., Bristol-Myers Squibb Company
    Inventors: Katherine E. Lewis, Serena Kimi Perna, Michael Carleton, Ke Xu, Penny Phillips, Dimple Pandya, Brian Wong, Julie Hambleton, Robert Sikorski, Emma Masteller, Kevin Hestir, David Bellovin, Janine Powers, Ernestine Lee
  • Anti-CSF1R antibody and anti-PD-1 antibody combination therapy for selected cancers
    Patent number: 11566076
    Abstract: Methods of treating cancer with antibodies that bind colony stimulating factor 1 receptor (CSF1R) in combination with PD-1/PD-L1 inhibitors are provided.
    Type: Grant
    Filed: March 4, 2020
    Date of Patent: January 31, 2023
    Assignees: Five Prime Therapeutics, Inc., Bristol-Myers Squibb Company
    Inventors: Brian Wong, Julie Hambleton, Robert Sikorski, Emma Masteller, Kevin Hestir, David Bellovin, Katherine E. Lewis
  • Anti-CSF1R antibody and agonistic anti-CD40 antibody combination therapy for cancer
    Patent number: 11559583
    Abstract: Methods of treating cancer with antibodies that bind colony stimulating factor 1 receptor (CSF1R) in combination with one or more immune stimulating agents are provided.
    Type: Grant
    Filed: February 10, 2020
    Date of Patent: January 24, 2023
    Assignee: Five Prime Therapeutics, Inc.
    Inventors: Emma Masteller, Thomas Brennan, David Bellovin, Kevin P. Baker, Brian Wong
  • Combination anti-CSF1R and anti-PD-1 antibody combination therapy for pancreatic cancer
    Patent number: 11421034
    Abstract: The present invention relates to methods of treating pancreatic cancer with particular dosage regimes of antibodies that bind colony stimulating factor 1 receptor (CSF1R) (e.g. cabiralizumab) in combination with antibodies that bind programmed cell death 1 (PD-1) (e.g. nivolumab).
    Type: Grant
    Filed: September 12, 2018
    Date of Patent: August 23, 2022
    Assignees: Five Prime Therapeutics, Inc., Bristol-Myers Squibb Company
    Inventors: Katherine E. Lewis, Serena Kimi Perna, Michael Carleton, Ke Xu, Penny Phillips, Dimple Pandya, Brian Wong, Julie Hambleton, Robert Sikorski, Emma Masteller, Kevin Hestir, David Bellovin, Janine Powers, Ernestine Lee
  • Anti-ROR1 antibodies
    Patent number: 11155615
    Abstract: The invention relates to antibodies, and in particular, to antibodies exhibiting specificity for Receptor tyrosine kinase-like Orphan Receptors (ROR), and to uses thereof, for example in the treatment of cancer. The invention extends to polynucleotide and polypeptide sequences encoding the antibodies, and therapeutic uses thereof, and to diagnostic kits comprising these molecules. The invention also extends to antibody-drug conjugates and to uses thereof in therapy.
    Type: Grant
    Filed: May 17, 2016
    Date of Patent: October 26, 2021
    Assignee: EUREKA THERAPEUTICS, INC.
    Inventors: Brian Wong, Emma Masteller, Cheng Liu, Yiyang Xu, Hong Liu, Su Yan, Jingyi Xiang, Pei Wang
  • Methods of Treating Conditions with Antibodies that Bind Colony Stimulating Factor 1 Receptor (CSF1R)
    Publication number: 20210317219
    Abstract: Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R) are provided. Such methods include, but are not limited to, methods of treating rheumatoid arthritis.
    Type: Application
    Filed: February 24, 2021
    Publication date: October 14, 2021
    Applicant: Five Prime Therapeutics, Inc.
    Inventors: Julie Hambleton, Emma Masteller, James Zanghi, Robert Sikorski, Hong Xiang
  • Methods of Treating Conditions with Antibodies that Bind Colony Stimulating Factor 1 Receptor (CSF1R)
    Publication number: 20210277130
    Abstract: Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R) are provided. Such methods include, but are not limited to, methods of treating rheumatoid arthritis and associated conditions, methods of treating systemic lupus erythematosus and associated conditions, and methods of treating multiple sclerosis.
    Type: Application
    Filed: February 11, 2021
    Publication date: September 9, 2021
    Applicant: Five Prime Therapeutics, Inc.
    Inventors: Brian Wong, Emma Masteller, Justin Wong, Haishan Lin
  • Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R)
    Patent number: 10982001
    Abstract: Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R) are provided. Such methods include, but are not limited to, methods of treating rheumatoid arthritis and associated conditions, methods of treating systemic lupus erythematosus and associated conditions, and methods of treating multiple sclerosis.
    Type: Grant
    Filed: May 11, 2016
    Date of Patent: April 20, 2021
    Assignee: Five Prime Therapeutics, Inc.
    Inventors: Brian Wong, Emma Masteller, Justin Wong, Haishan Lin
  • Methods of Treating Conditions with Antibodies that Bind Colony Stimulating Factor 1 Receptor (CSF1R)
    Publication number: 20210107986
    Abstract: Methods of reducing cytokine levels and methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R) are provided. Such methods include, but are not limited to, methods of treating inflammatory conditions, such as rheumatoid arthritis.
    Type: Application
    Filed: September 21, 2020
    Publication date: April 15, 2021
    Applicant: Five Prime Therapeutics, Inc.
    Inventors: Brian Wong, Emma Masteller, Kris Reedquist
  • Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R)
    Patent number: 10975153
    Abstract: Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R) are provided. Such methods include, but are not limited to, methods of treating rheumatoid arthritis.
    Type: Grant
    Filed: June 18, 2015
    Date of Patent: April 13, 2021
    Assignee: Five Prime Therapeutics, Inc.
    Inventors: Julie Hambleton, Emma Masteller, James Zanghi, Robert Sikorski, Hong Xiang
  • Combination Anti-CSF1R and Anti-PD-1 Antibody Combination Therapy for Pancreatic Cancer
    Publication number: 20210009697
    Abstract: The present invention relates to methods of treating pancreatic cancer with particular dosage regimes of antibodies that bind colony stimulating factor 1 receptor (CSF1R) (e.g. cabiralizumab) in combination with antibodies that bind programmed cell death 1 (PD-1) (e.g. nivolumab).
    Type: Application
    Filed: September 12, 2018
    Publication date: January 14, 2021
    Applicants: Five Prime Therapeutics, Inc., Bristol-Myers Squibb Company
    Inventors: Katherine E. Lewis, Serena Kimi Perna, Michael Carleton, Ke Xu, Penny Phillips, Dimple Pandya, Brian Wong, Julie Hambleton, Robert Sikorski, Emma Masteller, Kevin Hestir, David Bellovin, Janine Powers, Ernestine Lee
  • Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R)
    Patent number: 10822421
    Abstract: Methods of reducing cytokine levels and methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R) are provided. Such methods include, but are not limited to, methods of treating inflammatory conditions, such as rheumatoid arthritis.
    Type: Grant
    Filed: January 24, 2019
    Date of Patent: November 3, 2020
    Assignee: Five Prime Therapeutics, Inc.
    Inventors: Brian Wong, Emma Masteller, Kris Reedquist
  • Anti-CSF1R Antibody and Anti-PD-1 Antibody Combination Therapy for Cancer
    Publication number: 20200299392
    Abstract: Methods of treating cancer with antibodies that bind colony stimulating factor 1 receptor (CSF1R) in combination with PD-1/PD-L1 inhibitors are provided.
    Type: Application
    Filed: March 4, 2020
    Publication date: September 24, 2020
    Applicants: Five Prime Therapeutics, Inc., Bristol-Myers Squibb Company
    Inventors: Brian Wong, Julie Hambleton, Robert Sikorski, Emma Masteller, Kevin Hestir, David Bellovin, Katherine E. Lewis
  • Combination Therapy for Cancer
    Publication number: 20200237927
    Abstract: Methods of treating cancer with antibodies that bind colony stimulating factor 1 receptor (CSF1R) in combination with one or more immune stimulating agents are provided.
    Type: Application
    Filed: February 10, 2020
    Publication date: July 30, 2020
    Applicant: Five Prime Therapeutics, Inc.
    Inventors: Emma Masteller, Thomas Brennan, David Bellovin, Kevin Baker, Brian Wong
  • Anti-CSF1R antibody and anti PD-1 antibody combination therapy for cancer
    Patent number: 10618967
    Abstract: Methods of treating cancer with antibodies that bind colony stimulating factor 1 receptor (CSF1R) in combination with PD-1/PD-L1 inhibitors are provided.
    Type: Grant
    Filed: January 9, 2019
    Date of Patent: April 14, 2020
    Assignees: Five Prime Therapeutics, Inc., Bristol-Myers Squibb Company
    Inventors: Brian Wong, Julie Hambleton, Robert Sikorski, Emma Masteller, Kevin Hestir, David Bellovin, Katherine E. Lewis
  • Methods of Treating Conditions with Antibodies that Bind Colony Stimulating Factor 1 Receptor (CSF1R)
    Publication number: 20190248908
    Abstract: Methods of reducing cytokine levels and methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R) are provided. Such methods include, but are not limited to, methods of treating inflammatory conditions, such as rheumatoid arthritis.
    Type: Application
    Filed: January 24, 2019
    Publication date: August 15, 2019
    Applicant: Five Prime Therapeutics, Inc.
    Inventors: Brian Wong, Emma Masteller, Kris Reedquist
  • Anti-CSF1R Antibody and Anti PD-1 Antibody Combination Therapy for Cancer
    Publication number: 20190202921
    Abstract: Methods of treating cancer with antibodies that bind colony stimulating factor 1 receptor (CSF1R) in combination with PD-1/PD-L1 inhibitors are provided.
    Type: Application
    Filed: January 9, 2019
    Publication date: July 4, 2019
    Applicants: Five Prime Therapeutics, Inc., Bristol-Myers Squibb Company
    Inventors: Brian Wong, Julie Hambleton, Robert Sikorski, Emma Masteller, Kevin Hestir, David Bellovin, Katherine E. Lewis
  • Anti-CSF1R antibody and anti PD-1 antibody combination therapy for cancer
    Patent number: 10221244
    Abstract: Methods of treating cancer with antibodies that bind colony stimulating factor 1 receptor (CSF1R) in combination with PD-1/PD-L1 inhibitors are provided.
    Type: Grant
    Filed: August 18, 2017
    Date of Patent: March 5, 2019
    Assignees: Five Prime Therapeutics, Inc., Bristol-Myers Squibb Company
    Inventors: Brian Wong, Julie Hambleton, Robert Sikorski, Emma Masteller, Kevin Hestir, David Bellovin, Katherine E. Lewis
  • Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R)
    Patent number: 10221243
    Abstract: Methods of reducing cytokine levels and methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R) are provided. Such methods include, but are not limited to, methods of treating inflammatory conditions, such as rheumatoid arthritis.
    Type: Grant
    Filed: May 13, 2016
    Date of Patent: March 5, 2019
    Assignee: Five Prime Therapeutics, Inc.
    Inventors: Brian Wong, Emma Masteller, Kris Reedquist